
Opinion|Videos|December 4, 2024
Strategies to Alleviate the Clinical and Economic Burden of LEMS
Author(s)Wade Iams, MD
Key Takeaways
- Early diagnosis and personalized treatment plans are crucial in reducing the economic impact of LEMS on patients and healthcare systems.
- Optimizing pharmacotherapy and utilizing telemedicine can decrease hospitalizations and facilitate ongoing patient management.
A medical expert discusses strategies that have successfully mitigated the economic impact of LEMS on patients and health care systems, and how a multidisciplinary approach can reduce the clinical and economic burden of LEMS on health care delivery.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What strategies have been successful in mitigating the economic impact of Lambert-Eaton myasthenic syndrome (LEMS) on patients and health care systems?
- How can a multidisciplinary approach reduce the clinical and economic burden of LEMS on health care delivery?
Advertisement
Related to this article

Research at ObesityWeek 2026 tracks rising obesity in Medicare, productivity losses, prior authorization denials, and GLP-1 persistence.

In 459 patients with FLT3-ITD AML given high-dose anthracycline induction, a high allelic ratio was not linked to survival.

From 9.6 million US diabetic retinopathy cases to a new FDA warning on GLP-1s, here are 5 things to know about diabetic eye disease this November.

The action is based on phase 3 VOLGA results, which were presented at the ESMO Congress 2026. They support a perioperative regimen that limits the antibody-drug conjugate to 3 cycles before bladder removal.

New CMS data let EBRI measure what employer plans owe after No Surprises Act arbitration: $8.39B in 2025, though premium impact is unclear.

In this part 2, Kirsten Axelsen, MS, discusses racial disparities, AI in prior authorization, and payers’ readiness for the next wave of CLL therapies.

Kirsten Axelsen, MS, discusses gaps in biomarker testing, nonmedical barriers, and utilization management from a new report on access to CLL care.
Advertisement
Advertisement
Trending on AJMC
1
ObesityWeek 2026: Studies Map GLP-1 Access Gaps, Obesity's Costs
2
FDA Approves Durvalumab Plus EV Before Surgery in Cisplatin-Ineligible MIBC
3
MM’s Vulnerability to CAR T Was a Happy Surprise: Nikhil C. Munshi, MD
4
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
5


